期刊文献+

精确病理诊断在甲状腺癌精准医疗中的意义 被引量:12

Accurate pathological diagnosis of thyroid cancer in the era of precision medicine
下载PDF
导出
摘要 甲状腺癌是近年来发病率上升最快的实体恶性肿瘤,其中绝大多数为滤泡细胞来源,以分化型甲状腺癌为主,包括甲状腺乳头状癌(papillary thyroid cancer,PTC)和滤泡癌(follicular thyroid cancer,FTC)。为实现甲状腺癌的精准预防、诊断和治疗,需要以精确病理诊断作为基础。本文分别从评估并降低甲状腺癌发生风险、术前精确诊断、预后和复发风险分层,以及指导晚期患者分子靶向治疗等方面来阐述精确病理诊断在甲状腺癌精准医疗中的意义。 Thyroid cancer is the malignant tumor with the most rapidly increasing incidence in recent years, the overwhelming majori- ty of which are derived from follicular cells. The most common tumor entity is differentiated thyroid cancer, which could be divided in- to papillary thyroid cancer and follicular thyroid cancer. The accurate pathological diagnosis of thyroid cancer is the cornerstone in the process of precision medicine which includes prevention, diagnosis and treatment. This review discusses the significance of accurate pathological diagnosis in the precision medicine of thyroid cancer based on the following four aspects: 1) the risk evaluation of thyroid cancer, 2) preoperative accurate diagnosis of thyroid nodules, 3) the risk stratification of prognosis and recurrence, and 4) the guid- ance of molecular targeted therapy in advanced patients.
作者 陈健 江亮
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2017年第4期181-185,共5页 Chinese Journal of Clinical Oncology
关键词 精确病理诊断 甲状腺癌 精准医疗 accurate pathological diagnosis, thyroid cancer, precision medicine
  • 相关文献

参考文献4

二级参考文献58

  • 1ZHURui-sen YUYong-li LUHan-kui LUOQuan-yong CHENLi-bo.Clinical study of 312 cases with matastatic differentiated thyroid cancer treated with large doses of ^(131)I[J].Chinese Medical Journal,2005(5):425-428. 被引量:10
  • 2翟凤英,何宇纳,马冠生,李艳平,王志宏,胡以松,赵丽云,崔朝辉,李园,杨晓光.中国城乡居民食物消费现状及变化趋势[J].中华流行病学杂志,2005,26(7):485-488. 被引量:206
  • 3Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction[J]. PloS One,2010,5(4) :e10312. 被引量:1
  • 4Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome[ J]. Cancer Res, 2010,70(9) : 3463-3472. 被引量:1
  • 5Schmitz-Drager B J, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus [ J ]. Urol Int, 2015,94 (1) : 1-24. 被引量:1
  • 6Lang JE, Wecsler JS, Press MF, et al. Molecular maskers for breast cancer diagnosis, prognosis and targeted therapy[ J]. J Surg Onco1,2015,111 ( 1 ) : 81-90. 被引量:1
  • 7Borrts E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing[ J]. BMC Cancer, 2011,11 : 406. 被引量:1
  • 8Rosell R, Carcereny E, Gervais R, et al. Edotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC) : a muhicentre, open-label, randomised phase 3 trial [J]. Lancet Oncol,2012,13(3) : 239-246. 被引量:1
  • 9Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours [ J ]. Histopathology ,2008,53 ( 3 ) :245-266. 被引量:1
  • 10WIEMANN B, STARNES CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective [J]. Pharmacal Ther, 1994 ,64 (3) : 529 - 564. 被引量:1

共引文献557

同被引文献84

引证文献12

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部